Disease Information & Support


The Word:


Generic name Pentostatin
Pronunciation pen-toh-STAT-in
Brand name(s), other common name(s) Nipent®
Drug type  Antimetabolite
How the drug is given Intravenously (IV)

Pentostatin is FDA approved as a single-agent treatment for both untreated and alfa-interferon-refractory hairy cell leukemia patients with active disease as defined by clinically significant anemia, neutropenia (abnormally low white blood count), thrombocytopenia (reduced platelet count), or disease-related symptoms.

Side effects needing medical attention: Fever; chills; bone pain; weakness and fatigue; lack of coordination, especially in walking; skin disorders; unusual decrease or increase in urination; cough; inflammation of the eye; flulike symptoms; confusion; depression; dizziness; drowsiness; nausea and vomiting; decreased appetite; diarrhea; headache.


For information on how to manage the costs of drug therapy, please see Financial Matters and Prescription Drug Coverage, or to speak with an Information Specialist, call (800) 955-4572.

last updated on Monday, October 15, 2012